nodes	percent_of_prediction	percent_of_DWPC	metapath
Lidocaine—SCN10A—skin cancer	0.453	1	CbGaD
Lidocaine—EGFR—Docetaxel—skin cancer	0.0893	0.209	CbGbCtD
Lidocaine—SLC22A5—Dactinomycin—skin cancer	0.0406	0.0951	CbGbCtD
Lidocaine—CYP1A2—Imiquimod—skin cancer	0.0324	0.0758	CbGbCtD
Lidocaine—CYP2C8—Vismodegib—skin cancer	0.029	0.0679	CbGbCtD
Lidocaine—CYP2A6—Fluorouracil—skin cancer	0.0209	0.0489	CbGbCtD
Lidocaine—CYP2C9—Vismodegib—skin cancer	0.0202	0.0473	CbGbCtD
Lidocaine—ABCB1—Vismodegib—skin cancer	0.0196	0.0459	CbGbCtD
Lidocaine—CYP1A2—Vemurafenib—skin cancer	0.0177	0.0415	CbGbCtD
Lidocaine—CYP3A4—Temozolomide—skin cancer	0.017	0.0397	CbGbCtD
Lidocaine—CYP3A4—Imiquimod—skin cancer	0.017	0.0397	CbGbCtD
Lidocaine—CYP2D6—Vemurafenib—skin cancer	0.0146	0.0342	CbGbCtD
Lidocaine—CYP1A2—Dacarbazine—skin cancer	0.0136	0.0318	CbGbCtD
Lidocaine—CYP3A4—Vismodegib—skin cancer	0.0117	0.0275	CbGbCtD
Lidocaine—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.0109	0.0255	CbGbCtD
Lidocaine—CYP3A7—Docetaxel—skin cancer	0.0109	0.0255	CbGbCtD
Lidocaine—ABCB1—Dactinomycin—skin cancer	0.0103	0.0241	CbGbCtD
Lidocaine—CYP2C8—Fluorouracil—skin cancer	0.0103	0.0241	CbGbCtD
Lidocaine—CYP3A4—Vemurafenib—skin cancer	0.00929	0.0218	CbGbCtD
Lidocaine—CYP3A5—Docetaxel—skin cancer	0.00817	0.0191	CbGbCtD
Lidocaine—CYP1A2—Fluorouracil—skin cancer	0.00797	0.0187	CbGbCtD
Lidocaine—CYP2C9—Fluorouracil—skin cancer	0.00718	0.0168	CbGbCtD
Lidocaine—ABCB1—Docetaxel—skin cancer	0.00532	0.0125	CbGbCtD
Lidocaine—CYP3A4—Docetaxel—skin cancer	0.00319	0.00746	CbGbCtD
Lidocaine—Levobupivacaine—SCN10A—skin cancer	0.0011	0.2	CrCbGaD
Lidocaine—Mepivacaine—SCN10A—skin cancer	0.000895	0.163	CrCbGaD
Lidocaine—Bupivacaine—SCN10A—skin cancer	0.000878	0.16	CrCbGaD
Lidocaine—Chloroprocaine—SCN10A—skin cancer	0.000832	0.152	CrCbGaD
Lidocaine—Ropivacaine—SCN10A—skin cancer	0.000708	0.129	CrCbGaD
Lidocaine—Tocainide—SCN10A—skin cancer	0.000665	0.121	CrCbGaD
Lidocaine—Skin exfoliation—Bleomycin—skin cancer	0.000502	0.00587	CcSEcCtD
Lidocaine—Numbness—Fluorouracil—skin cancer	0.000493	0.00577	CcSEcCtD
Lidocaine—Nervous system disorder—Vismodegib—skin cancer	0.000492	0.00575	CcSEcCtD
Lidocaine—Neuropathy peripheral—Vemurafenib—skin cancer	0.000476	0.00557	CcSEcCtD
Lidocaine—Sensory loss—Fluorouracil—skin cancer	0.000472	0.00552	CcSEcCtD
Lidocaine—Tenderness—Fluorouracil—skin cancer	0.000469	0.00548	CcSEcCtD
Lidocaine—Sweating increased—Imiquimod—skin cancer	0.000452	0.00529	CcSEcCtD
Lidocaine—Redness—Docetaxel—skin cancer	0.000437	0.00511	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Vismodegib—skin cancer	0.000433	0.00506	CcSEcCtD
Lidocaine—Dysarthria—Fluorouracil—skin cancer	0.000432	0.00506	CcSEcCtD
Lidocaine—Pain—Vismodegib—skin cancer	0.000429	0.00502	CcSEcCtD
Lidocaine—Depressed level of consciousness—Temozolomide—skin cancer	0.000428	0.00501	CcSEcCtD
Lidocaine—Urinary incontinence—Temozolomide—skin cancer	0.000428	0.00501	CcSEcCtD
Lidocaine—Disorientation—Bleomycin—skin cancer	0.000427	0.00499	CcSEcCtD
Lidocaine—Burning sensation—Docetaxel—skin cancer	0.000425	0.00497	CcSEcCtD
Lidocaine—Skin exfoliation—Temozolomide—skin cancer	0.000424	0.00496	CcSEcCtD
Lidocaine—Neuropathy—Temozolomide—skin cancer	0.000417	0.00487	CcSEcCtD
Lidocaine—Procainamide—SCN10A—skin cancer	0.000411	0.0749	CrCbGaD
Lidocaine—Throat sore—Docetaxel—skin cancer	0.000409	0.00479	CcSEcCtD
Lidocaine—Eye disorder—Vemurafenib—skin cancer	0.000407	0.00477	CcSEcCtD
Lidocaine—Neuropathy peripheral—Imiquimod—skin cancer	0.000406	0.00475	CcSEcCtD
Lidocaine—Oropharyngeal discomfort—Docetaxel—skin cancer	0.000406	0.00475	CcSEcCtD
Lidocaine—Cardiac disorder—Vemurafenib—skin cancer	0.000405	0.00473	CcSEcCtD
Lidocaine—Dermatitis contact—Fluorouracil—skin cancer	0.000404	0.00473	CcSEcCtD
Lidocaine—Angiopathy—Vemurafenib—skin cancer	0.000396	0.00463	CcSEcCtD
Lidocaine—Chills—Vemurafenib—skin cancer	0.000391	0.00458	CcSEcCtD
Lidocaine—Erythema—Vemurafenib—skin cancer	0.000379	0.00444	CcSEcCtD
Lidocaine—Haemoglobin—Imiquimod—skin cancer	0.000374	0.00437	CcSEcCtD
Lidocaine—Coma—Fluorouracil—skin cancer	0.000374	0.00437	CcSEcCtD
Lidocaine—Rhinitis—Imiquimod—skin cancer	0.000373	0.00436	CcSEcCtD
Lidocaine—Haemorrhage—Imiquimod—skin cancer	0.000372	0.00435	CcSEcCtD
Lidocaine—Dysgeusia—Vemurafenib—skin cancer	0.000372	0.00435	CcSEcCtD
Lidocaine—Back pain—Vemurafenib—skin cancer	0.000367	0.00429	CcSEcCtD
Lidocaine—Asthenia—Vismodegib—skin cancer	0.00036	0.00421	CcSEcCtD
Lidocaine—Visual impairment—Imiquimod—skin cancer	0.000358	0.00419	CcSEcCtD
Lidocaine—Euphoric mood—Fluorouracil—skin cancer	0.000351	0.00411	CcSEcCtD
Lidocaine—Eye disorder—Imiquimod—skin cancer	0.000347	0.00406	CcSEcCtD
Lidocaine—Tinnitus—Imiquimod—skin cancer	0.000347	0.00406	CcSEcCtD
Lidocaine—Flushing—Imiquimod—skin cancer	0.000345	0.00404	CcSEcCtD
Lidocaine—Angiopathy—Imiquimod—skin cancer	0.000337	0.00395	CcSEcCtD
Lidocaine—Immune system disorder—Imiquimod—skin cancer	0.000336	0.00393	CcSEcCtD
Lidocaine—Chills—Imiquimod—skin cancer	0.000334	0.0039	CcSEcCtD
Lidocaine—Disorientation—Fluorouracil—skin cancer	0.000332	0.00388	CcSEcCtD
Lidocaine—Bronchospasm—Bleomycin—skin cancer	0.000325	0.0038	CcSEcCtD
Lidocaine—Oropharyngeal pain—Docetaxel—skin cancer	0.000324	0.0038	CcSEcCtD
Lidocaine—Erythema—Imiquimod—skin cancer	0.000324	0.00379	CcSEcCtD
Lidocaine—Diplopia—Temozolomide—skin cancer	0.000322	0.00377	CcSEcCtD
Lidocaine—Vomiting—Vismodegib—skin cancer	0.000319	0.00373	CcSEcCtD
Lidocaine—Rash—Vismodegib—skin cancer	0.000316	0.0037	CcSEcCtD
Lidocaine—Dermatitis—Vismodegib—skin cancer	0.000316	0.00369	CcSEcCtD
Lidocaine—Back pain—Imiquimod—skin cancer	0.000313	0.00366	CcSEcCtD
Lidocaine—Dermatitis bullous—Fluorouracil—skin cancer	0.00031	0.00363	CcSEcCtD
Lidocaine—Anaphylactic shock—Vemurafenib—skin cancer	0.00031	0.00362	CcSEcCtD
Lidocaine—Dysphagia—Dactinomycin—skin cancer	0.000308	0.0036	CcSEcCtD
Lidocaine—Nervous system disorder—Vemurafenib—skin cancer	0.000304	0.00355	CcSEcCtD
Lidocaine—Nausea—Vismodegib—skin cancer	0.000298	0.00348	CcSEcCtD
Lidocaine—Agitation—Imiquimod—skin cancer	0.000297	0.00348	CcSEcCtD
Lidocaine—Osteoarthritis—Fluorouracil—skin cancer	0.000297	0.00347	CcSEcCtD
Lidocaine—Angioedema—Imiquimod—skin cancer	0.000296	0.00346	CcSEcCtD
Lidocaine—Hypotension—Vemurafenib—skin cancer	0.000289	0.00339	CcSEcCtD
Lidocaine—Stomatitis—Bleomycin—skin cancer	0.000287	0.00335	CcSEcCtD
Lidocaine—Loss of consciousness—Imiquimod—skin cancer	0.000284	0.00333	CcSEcCtD
Lidocaine—Cardiac arrest—Fluorouracil—skin cancer	0.000282	0.0033	CcSEcCtD
Lidocaine—Skin exfoliation—Docetaxel—skin cancer	0.000282	0.0033	CcSEcCtD
Lidocaine—Convulsion—Imiquimod—skin cancer	0.00028	0.00328	CcSEcCtD
Lidocaine—Hypertension—Imiquimod—skin cancer	0.000279	0.00327	CcSEcCtD
Lidocaine—Dysphagia—Temozolomide—skin cancer	0.000278	0.00326	CcSEcCtD
Lidocaine—Neuropathy—Docetaxel—skin cancer	0.000277	0.00324	CcSEcCtD
Lidocaine—Chest pain—Imiquimod—skin cancer	0.000276	0.00322	CcSEcCtD
Lidocaine—Anxiety—Imiquimod—skin cancer	0.000275	0.00321	CcSEcCtD
Lidocaine—Sweating increased—Temozolomide—skin cancer	0.000271	0.00317	CcSEcCtD
Lidocaine—Stomatitis—Dactinomycin—skin cancer	0.000267	0.00313	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000267	0.00313	CcSEcCtD
Lidocaine—Haemoglobin—Bleomycin—skin cancer	0.000265	0.00311	CcSEcCtD
Lidocaine—Oedema—Imiquimod—skin cancer	0.000264	0.00309	CcSEcCtD
Lidocaine—Haemorrhage—Bleomycin—skin cancer	0.000264	0.00309	CcSEcCtD
Lidocaine—Lightheadedness—Docetaxel—skin cancer	0.000264	0.00309	CcSEcCtD
Lidocaine—Hypoaesthesia—Bleomycin—skin cancer	0.000263	0.00307	CcSEcCtD
Lidocaine—Shock—Imiquimod—skin cancer	0.00026	0.00304	CcSEcCtD
Lidocaine—Nervous system disorder—Imiquimod—skin cancer	0.000259	0.00303	CcSEcCtD
Lidocaine—Dysphagia—Fluorouracil—skin cancer	0.000256	0.003	CcSEcCtD
Lidocaine—Hyperhidrosis—Imiquimod—skin cancer	0.000255	0.00299	CcSEcCtD
Lidocaine—Flushing—Bleomycin—skin cancer	0.000245	0.00287	CcSEcCtD
Lidocaine—Neuropathy peripheral—Temozolomide—skin cancer	0.000243	0.00285	CcSEcCtD
Lidocaine—Stomatitis—Temozolomide—skin cancer	0.000242	0.00283	CcSEcCtD
Lidocaine—Paraesthesia—Imiquimod—skin cancer	0.000237	0.00277	CcSEcCtD
Lidocaine—Chills—Bleomycin—skin cancer	0.000237	0.00277	CcSEcCtD
Lidocaine—Dyspnoea—Imiquimod—skin cancer	0.000235	0.00275	CcSEcCtD
Lidocaine—Somnolence—Imiquimod—skin cancer	0.000235	0.00275	CcSEcCtD
Lidocaine—Erythema—Bleomycin—skin cancer	0.00023	0.00269	CcSEcCtD
Lidocaine—Flushing—Dactinomycin—skin cancer	0.000229	0.00267	CcSEcCtD
Lidocaine—Hypersensitivity—Vemurafenib—skin cancer	0.000228	0.00267	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Imiquimod—skin cancer	0.000228	0.00267	CcSEcCtD
Lidocaine—Visual disturbance—Docetaxel—skin cancer	0.000226	0.00264	CcSEcCtD
Lidocaine—Pain—Imiquimod—skin cancer	0.000226	0.00264	CcSEcCtD
Lidocaine—Neuropathy peripheral—Fluorouracil—skin cancer	0.000224	0.00262	CcSEcCtD
Lidocaine—Dermatitis bullous—Docetaxel—skin cancer	0.000224	0.00262	CcSEcCtD
Lidocaine—Haemoglobin—Temozolomide—skin cancer	0.000224	0.00262	CcSEcCtD
Lidocaine—Stomatitis—Fluorouracil—skin cancer	0.000223	0.00261	CcSEcCtD
Lidocaine—Haemorrhage—Temozolomide—skin cancer	0.000223	0.00261	CcSEcCtD
Lidocaine—Asthenia—Vemurafenib—skin cancer	0.000222	0.0026	CcSEcCtD
Lidocaine—Hypoaesthesia—Temozolomide—skin cancer	0.000222	0.00259	CcSEcCtD
Lidocaine—Chills—Dactinomycin—skin cancer	0.000221	0.00259	CcSEcCtD
Lidocaine—Feeling abnormal—Imiquimod—skin cancer	0.000218	0.00255	CcSEcCtD
Lidocaine—Visual impairment—Temozolomide—skin cancer	0.000215	0.00251	CcSEcCtD
Lidocaine—Erythema—Dactinomycin—skin cancer	0.000214	0.00251	CcSEcCtD
Lidocaine—Urticaria—Imiquimod—skin cancer	0.00021	0.00245	CcSEcCtD
Lidocaine—Eye disorder—Temozolomide—skin cancer	0.000208	0.00244	CcSEcCtD
Lidocaine—Tinnitus—Temozolomide—skin cancer	0.000208	0.00243	CcSEcCtD
Lidocaine—Flushing—Temozolomide—skin cancer	0.000207	0.00242	CcSEcCtD
Lidocaine—Cardiac disorder—Temozolomide—skin cancer	0.000207	0.00242	CcSEcCtD
Lidocaine—Haemoglobin—Fluorouracil—skin cancer	0.000206	0.00241	CcSEcCtD
Lidocaine—Rhinitis—Fluorouracil—skin cancer	0.000206	0.00241	CcSEcCtD
Lidocaine—Haemorrhage—Fluorouracil—skin cancer	0.000205	0.0024	CcSEcCtD
Lidocaine—Dizziness—Vemurafenib—skin cancer	0.000205	0.0024	CcSEcCtD
Lidocaine—Hypoaesthesia—Fluorouracil—skin cancer	0.000204	0.00239	CcSEcCtD
Lidocaine—Angiopathy—Temozolomide—skin cancer	0.000202	0.00236	CcSEcCtD
Lidocaine—Immune system disorder—Temozolomide—skin cancer	0.000201	0.00235	CcSEcCtD
Lidocaine—Chills—Temozolomide—skin cancer	0.0002	0.00234	CcSEcCtD
Lidocaine—Vomiting—Vemurafenib—skin cancer	0.000197	0.0023	CcSEcCtD
Lidocaine—Chest pain—Bleomycin—skin cancer	0.000196	0.00229	CcSEcCtD
Lidocaine—Rash—Vemurafenib—skin cancer	0.000195	0.00228	CcSEcCtD
Lidocaine—Dermatitis—Vemurafenib—skin cancer	0.000195	0.00228	CcSEcCtD
Lidocaine—Hypersensitivity—Imiquimod—skin cancer	0.000195	0.00228	CcSEcCtD
Lidocaine—Headache—Vemurafenib—skin cancer	0.000194	0.00227	CcSEcCtD
Lidocaine—Erythema—Temozolomide—skin cancer	0.000194	0.00227	CcSEcCtD
Lidocaine—Dysgeusia—Temozolomide—skin cancer	0.00019	0.00222	CcSEcCtD
Lidocaine—Asthenia—Imiquimod—skin cancer	0.00019	0.00222	CcSEcCtD
Lidocaine—Confusional state—Bleomycin—skin cancer	0.000189	0.00221	CcSEcCtD
Lidocaine—Oedema—Bleomycin—skin cancer	0.000188	0.0022	CcSEcCtD
Lidocaine—Anaphylactic shock—Bleomycin—skin cancer	0.000188	0.0022	CcSEcCtD
Lidocaine—Back pain—Temozolomide—skin cancer	0.000188	0.00219	CcSEcCtD
Lidocaine—Dysphagia—Docetaxel—skin cancer	0.000185	0.00217	CcSEcCtD
Lidocaine—Nausea—Vemurafenib—skin cancer	0.000184	0.00215	CcSEcCtD
Lidocaine—Vision blurred—Temozolomide—skin cancer	0.000183	0.00214	CcSEcCtD
Lidocaine—Bronchospasm—Docetaxel—skin cancer	0.000182	0.00213	CcSEcCtD
Lidocaine—Tremor—Temozolomide—skin cancer	0.000182	0.00213	CcSEcCtD
Lidocaine—Erythema—Fluorouracil—skin cancer	0.000179	0.00209	CcSEcCtD
Lidocaine—Agitation—Temozolomide—skin cancer	0.000178	0.00209	CcSEcCtD
Lidocaine—Angioedema—Temozolomide—skin cancer	0.000177	0.00207	CcSEcCtD
Lidocaine—Hypotension—Bleomycin—skin cancer	0.000175	0.00205	CcSEcCtD
Lidocaine—Oedema—Dactinomycin—skin cancer	0.000175	0.00205	CcSEcCtD
Lidocaine—Dizziness—Imiquimod—skin cancer	0.000175	0.00204	CcSEcCtD
Lidocaine—Paraesthesia—Bleomycin—skin cancer	0.000168	0.00197	CcSEcCtD
Lidocaine—Vision blurred—Fluorouracil—skin cancer	0.000168	0.00197	CcSEcCtD
Lidocaine—Convulsion—Temozolomide—skin cancer	0.000168	0.00197	CcSEcCtD
Lidocaine—Vomiting—Imiquimod—skin cancer	0.000168	0.00196	CcSEcCtD
Lidocaine—Hypertension—Temozolomide—skin cancer	0.000167	0.00196	CcSEcCtD
Lidocaine—Dyspnoea—Bleomycin—skin cancer	0.000167	0.00196	CcSEcCtD
Lidocaine—Rash—Imiquimod—skin cancer	0.000167	0.00195	CcSEcCtD
Lidocaine—Dermatitis—Imiquimod—skin cancer	0.000166	0.00195	CcSEcCtD
Lidocaine—Headache—Imiquimod—skin cancer	0.000165	0.00194	CcSEcCtD
Lidocaine—Anxiety—Temozolomide—skin cancer	0.000165	0.00192	CcSEcCtD
Lidocaine—Neuropathy peripheral—Docetaxel—skin cancer	0.000162	0.00189	CcSEcCtD
Lidocaine—Stomatitis—Docetaxel—skin cancer	0.000161	0.00188	CcSEcCtD
Lidocaine—Pain—Bleomycin—skin cancer	0.00016	0.00188	CcSEcCtD
Lidocaine—Confusional state—Temozolomide—skin cancer	0.00016	0.00187	CcSEcCtD
Lidocaine—Oedema—Temozolomide—skin cancer	0.000158	0.00185	CcSEcCtD
Lidocaine—Anaphylactic shock—Temozolomide—skin cancer	0.000158	0.00185	CcSEcCtD
Lidocaine—Nausea—Imiquimod—skin cancer	0.000157	0.00184	CcSEcCtD
Lidocaine—Nervous system disorder—Temozolomide—skin cancer	0.000155	0.00182	CcSEcCtD
Lidocaine—Convulsion—Fluorouracil—skin cancer	0.000155	0.00181	CcSEcCtD
Lidocaine—Feeling abnormal—Bleomycin—skin cancer	0.000155	0.00181	CcSEcCtD
Lidocaine—Hyperhidrosis—Temozolomide—skin cancer	0.000153	0.00179	CcSEcCtD
Lidocaine—Chest pain—Fluorouracil—skin cancer	0.000152	0.00178	CcSEcCtD
Lidocaine—Pain—Dactinomycin—skin cancer	0.00015	0.00175	CcSEcCtD
Lidocaine—Urticaria—Bleomycin—skin cancer	0.000149	0.00174	CcSEcCtD
Lidocaine—Haemoglobin—Docetaxel—skin cancer	0.000149	0.00174	CcSEcCtD
Lidocaine—Rhinitis—Docetaxel—skin cancer	0.000149	0.00174	CcSEcCtD
Lidocaine—Haemorrhage—Docetaxel—skin cancer	0.000148	0.00173	CcSEcCtD
Lidocaine—Hypoaesthesia—Docetaxel—skin cancer	0.000147	0.00172	CcSEcCtD
Lidocaine—Confusional state—Fluorouracil—skin cancer	0.000147	0.00172	CcSEcCtD
Lidocaine—Oedema—Fluorouracil—skin cancer	0.000146	0.00171	CcSEcCtD
Lidocaine—Anaphylactic shock—Fluorouracil—skin cancer	0.000146	0.00171	CcSEcCtD
Lidocaine—Feeling abnormal—Dactinomycin—skin cancer	0.000144	0.00169	CcSEcCtD
Lidocaine—Nervous system disorder—Fluorouracil—skin cancer	0.000143	0.00167	CcSEcCtD
Lidocaine—Visual impairment—Docetaxel—skin cancer	0.000143	0.00167	CcSEcCtD
Lidocaine—Paraesthesia—Temozolomide—skin cancer	0.000142	0.00166	CcSEcCtD
Lidocaine—Dyspnoea—Temozolomide—skin cancer	0.000141	0.00165	CcSEcCtD
Lidocaine—Somnolence—Temozolomide—skin cancer	0.000141	0.00165	CcSEcCtD
Lidocaine—Eye disorder—Docetaxel—skin cancer	0.000138	0.00162	CcSEcCtD
Lidocaine—Hypersensitivity—Bleomycin—skin cancer	0.000138	0.00162	CcSEcCtD
Lidocaine—Flushing—Docetaxel—skin cancer	0.000138	0.00161	CcSEcCtD
Lidocaine—Cardiac disorder—Docetaxel—skin cancer	0.000138	0.00161	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Temozolomide—skin cancer	0.000137	0.0016	CcSEcCtD
Lidocaine—Hypotension—Fluorouracil—skin cancer	0.000136	0.00159	CcSEcCtD
Lidocaine—Pain—Temozolomide—skin cancer	0.000135	0.00158	CcSEcCtD
Lidocaine—Asthenia—Bleomycin—skin cancer	0.000135	0.00157	CcSEcCtD
Lidocaine—Angiopathy—Docetaxel—skin cancer	0.000134	0.00157	CcSEcCtD
Lidocaine—Immune system disorder—Docetaxel—skin cancer	0.000134	0.00157	CcSEcCtD
Lidocaine—Chills—Docetaxel—skin cancer	0.000133	0.00156	CcSEcCtD
Lidocaine—Paraesthesia—Fluorouracil—skin cancer	0.000131	0.00153	CcSEcCtD
Lidocaine—Feeling abnormal—Temozolomide—skin cancer	0.00013	0.00153	CcSEcCtD
Lidocaine—Dyspnoea—Fluorouracil—skin cancer	0.00013	0.00152	CcSEcCtD
Lidocaine—Somnolence—Fluorouracil—skin cancer	0.00013	0.00152	CcSEcCtD
Lidocaine—Erythema—Docetaxel—skin cancer	0.000129	0.00151	CcSEcCtD
Lidocaine—Hypersensitivity—Dactinomycin—skin cancer	0.000129	0.00151	CcSEcCtD
Lidocaine—Dysgeusia—Docetaxel—skin cancer	0.000126	0.00148	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000126	0.00147	CcSEcCtD
Lidocaine—Urticaria—Temozolomide—skin cancer	0.000126	0.00147	CcSEcCtD
Lidocaine—Asthenia—Dactinomycin—skin cancer	0.000126	0.00147	CcSEcCtD
Lidocaine—Back pain—Docetaxel—skin cancer	0.000125	0.00146	CcSEcCtD
Lidocaine—Pain—Fluorouracil—skin cancer	0.000125	0.00146	CcSEcCtD
Lidocaine—Feeling abnormal—Fluorouracil—skin cancer	0.00012	0.00141	CcSEcCtD
Lidocaine—Vomiting—Bleomycin—skin cancer	0.000119	0.0014	CcSEcCtD
Lidocaine—Rash—Bleomycin—skin cancer	0.000118	0.00138	CcSEcCtD
Lidocaine—Dermatitis—Bleomycin—skin cancer	0.000118	0.00138	CcSEcCtD
Lidocaine—Hypersensitivity—Temozolomide—skin cancer	0.000117	0.00136	CcSEcCtD
Lidocaine—Urticaria—Fluorouracil—skin cancer	0.000116	0.00136	CcSEcCtD
Lidocaine—Asthenia—Temozolomide—skin cancer	0.000114	0.00133	CcSEcCtD
Lidocaine—Loss of consciousness—Docetaxel—skin cancer	0.000113	0.00133	CcSEcCtD
Lidocaine—Convulsion—Docetaxel—skin cancer	0.000112	0.00131	CcSEcCtD
Lidocaine—Nausea—Bleomycin—skin cancer	0.000111	0.0013	CcSEcCtD
Lidocaine—Hypertension—Docetaxel—skin cancer	0.000111	0.0013	CcSEcCtD
Lidocaine—Vomiting—Dactinomycin—skin cancer	0.000111	0.0013	CcSEcCtD
Lidocaine—Rash—Dactinomycin—skin cancer	0.00011	0.00129	CcSEcCtD
Lidocaine—Chest pain—Docetaxel—skin cancer	0.00011	0.00128	CcSEcCtD
Lidocaine—Hypersensitivity—Fluorouracil—skin cancer	0.000107	0.00126	CcSEcCtD
Lidocaine—Confusional state—Docetaxel—skin cancer	0.000106	0.00124	CcSEcCtD
Lidocaine—Anaphylactic shock—Docetaxel—skin cancer	0.000105	0.00123	CcSEcCtD
Lidocaine—Oedema—Docetaxel—skin cancer	0.000105	0.00123	CcSEcCtD
Lidocaine—Dizziness—Temozolomide—skin cancer	0.000105	0.00122	CcSEcCtD
Lidocaine—Nausea—Dactinomycin—skin cancer	0.000104	0.00122	CcSEcCtD
Lidocaine—Shock—Docetaxel—skin cancer	0.000104	0.00121	CcSEcCtD
Lidocaine—Nervous system disorder—Docetaxel—skin cancer	0.000103	0.00121	CcSEcCtD
Lidocaine—Vomiting—Temozolomide—skin cancer	0.000101	0.00118	CcSEcCtD
Lidocaine—Rash—Temozolomide—skin cancer	9.98e-05	0.00117	CcSEcCtD
Lidocaine—Dermatitis—Temozolomide—skin cancer	9.97e-05	0.00117	CcSEcCtD
Lidocaine—Headache—Temozolomide—skin cancer	9.92e-05	0.00116	CcSEcCtD
Lidocaine—Hypotension—Docetaxel—skin cancer	9.84e-05	0.00115	CcSEcCtD
Lidocaine—Dizziness—Fluorouracil—skin cancer	9.64e-05	0.00113	CcSEcCtD
Lidocaine—Paraesthesia—Docetaxel—skin cancer	9.45e-05	0.00111	CcSEcCtD
Lidocaine—Nausea—Temozolomide—skin cancer	9.4e-05	0.0011	CcSEcCtD
Lidocaine—Dyspnoea—Docetaxel—skin cancer	9.38e-05	0.0011	CcSEcCtD
Lidocaine—Somnolence—Docetaxel—skin cancer	9.36e-05	0.00109	CcSEcCtD
Lidocaine—Vomiting—Fluorouracil—skin cancer	9.27e-05	0.00108	CcSEcCtD
Lidocaine—Rash—Fluorouracil—skin cancer	9.2e-05	0.00108	CcSEcCtD
Lidocaine—Dermatitis—Fluorouracil—skin cancer	9.19e-05	0.00107	CcSEcCtD
Lidocaine—Headache—Fluorouracil—skin cancer	9.14e-05	0.00107	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Docetaxel—skin cancer	9.09e-05	0.00106	CcSEcCtD
Lidocaine—Pain—Docetaxel—skin cancer	9e-05	0.00105	CcSEcCtD
Lidocaine—Feeling abnormal—Docetaxel—skin cancer	8.67e-05	0.00101	CcSEcCtD
Lidocaine—Nausea—Fluorouracil—skin cancer	8.66e-05	0.00101	CcSEcCtD
Lidocaine—Hypersensitivity—Docetaxel—skin cancer	7.76e-05	0.000907	CcSEcCtD
Lidocaine—Asthenia—Docetaxel—skin cancer	7.55e-05	0.000884	CcSEcCtD
Lidocaine—Dizziness—Docetaxel—skin cancer	6.96e-05	0.000814	CcSEcCtD
Lidocaine—Vomiting—Docetaxel—skin cancer	6.69e-05	0.000783	CcSEcCtD
Lidocaine—Rash—Docetaxel—skin cancer	6.64e-05	0.000776	CcSEcCtD
Lidocaine—Dermatitis—Docetaxel—skin cancer	6.63e-05	0.000776	CcSEcCtD
Lidocaine—Headache—Docetaxel—skin cancer	6.59e-05	0.000771	CcSEcCtD
Lidocaine—Nausea—Docetaxel—skin cancer	6.25e-05	0.000731	CcSEcCtD
Lidocaine—SCN5A—SIDS Susceptibility Pathways—IL6—skin cancer	2.67e-05	0.000919	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—FOXO4—skin cancer	2.63e-05	0.000908	CbGpPWpGaD
Lidocaine—SCN10A—Axon guidance—KRAS—skin cancer	2.6e-05	0.000895	CbGpPWpGaD
Lidocaine—EGFR—Regulation of Actin Cytoskeleton—NRAS—skin cancer	2.59e-05	0.000892	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling of activated FGFR—NRAS—skin cancer	2.59e-05	0.000892	CbGpPWpGaD
Lidocaine—EGFR—Disease—CSPG4—skin cancer	2.56e-05	0.000881	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB4—NRAS—skin cancer	2.55e-05	0.000877	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—FOXO4—skin cancer	2.53e-05	0.000872	CbGpPWpGaD
Lidocaine—EGFR—ErbB1 downstream signaling—HRAS—skin cancer	2.5e-05	0.000863	CbGpPWpGaD
Lidocaine—SCN9A—Axon guidance—HRAS—skin cancer	2.49e-05	0.000859	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PLIN2—skin cancer	2.46e-05	0.000847	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—BRAF—skin cancer	2.44e-05	0.000842	CbGpPWpGaD
Lidocaine—EGFR—Downstream signal transduction—NRAS—skin cancer	2.43e-05	0.000838	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—NRAS—skin cancer	2.43e-05	0.000838	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR—NRAS—skin cancer	2.42e-05	0.000834	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB2—NRAS—skin cancer	2.41e-05	0.00083	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	2.4e-05	0.000828	CbGpPWpGaD
Lidocaine—EGFR—DAP12 signaling—NRAS—skin cancer	2.4e-05	0.000826	CbGpPWpGaD
Lidocaine—SCN9A—Axon guidance—IL6—skin cancer	2.39e-05	0.000822	CbGpPWpGaD
Lidocaine—EGFR—Spinal Cord Injury—TP53—skin cancer	2.38e-05	0.000822	CbGpPWpGaD
Lidocaine—SCN3A—Axon guidance—HRAS—skin cancer	2.38e-05	0.000822	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PTCH2—skin cancer	2.36e-05	0.000814	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—skin cancer	2.36e-05	0.000814	CbGpPWpGaD
Lidocaine—EGFR—MAPK Signaling Pathway—NRAS—skin cancer	2.35e-05	0.00081	CbGpPWpGaD
Lidocaine—EGFR—Signaling by SCF-KIT—KRAS—skin cancer	2.33e-05	0.000802	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—NRAS—skin cancer	2.33e-05	0.000801	CbGpPWpGaD
Lidocaine—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	2.3e-05	0.000792	CbGpPWpGaD
Lidocaine—SCN2A—Axon guidance—HRAS—skin cancer	2.29e-05	0.000789	CbGpPWpGaD
Lidocaine—SCN4A—Axon guidance—HRAS—skin cancer	2.29e-05	0.000789	CbGpPWpGaD
Lidocaine—SCN3A—Axon guidance—IL6—skin cancer	2.28e-05	0.000786	CbGpPWpGaD
Lidocaine—EGFR—DAP12 interactions—NRAS—skin cancer	2.25e-05	0.000777	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR in disease—NRAS—skin cancer	2.25e-05	0.000777	CbGpPWpGaD
Lidocaine—EGFR—Fc epsilon receptor (FCERI) signaling—NRAS—skin cancer	2.25e-05	0.000777	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PLIN2—skin cancer	2.25e-05	0.000776	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—NRAS—skin cancer	2.23e-05	0.00077	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—NRAS—skin cancer	2.23e-05	0.00077	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR—NRAS—skin cancer	2.23e-05	0.00077	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling of activated FGFR—KRAS—skin cancer	2.23e-05	0.000767	CbGpPWpGaD
Lidocaine—EGFR—Regulation of Actin Cytoskeleton—KRAS—skin cancer	2.23e-05	0.000767	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR in Cancer—NRAS—skin cancer	2.21e-05	0.000763	CbGpPWpGaD
Lidocaine—SCN10A—Axon guidance—HRAS—skin cancer	2.21e-05	0.000761	CbGpPWpGaD
Lidocaine—EGFR—Signaling by PDGF—NRAS—skin cancer	2.2e-05	0.00076	CbGpPWpGaD
Lidocaine—EGFR—Integrated Breast Cancer Pathway—KRAS—skin cancer	2.2e-05	0.000759	CbGpPWpGaD
Lidocaine—SCN4A—Axon guidance—IL6—skin cancer	2.19e-05	0.000755	CbGpPWpGaD
Lidocaine—SCN2A—Axon guidance—IL6—skin cancer	2.19e-05	0.000755	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB4—KRAS—skin cancer	2.19e-05	0.000755	CbGpPWpGaD
Lidocaine—EGFR—Spinal Cord Injury—IL6—skin cancer	2.18e-05	0.000752	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—NRAS—skin cancer	2.15e-05	0.000742	CbGpPWpGaD
Lidocaine—SCN5A—Axon guidance—NRAS—skin cancer	2.12e-05	0.000731	CbGpPWpGaD
Lidocaine—SCN10A—Axon guidance—IL6—skin cancer	2.11e-05	0.000728	CbGpPWpGaD
Lidocaine—EGFR—Downstream signal transduction—KRAS—skin cancer	2.09e-05	0.000721	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—KRAS—skin cancer	2.09e-05	0.000721	CbGpPWpGaD
Lidocaine—EGFR—B Cell Activation—NRAS—skin cancer	2.09e-05	0.000719	CbGpPWpGaD
Lidocaine—EGFR—EGF/EGFR Signaling Pathway—KRAS—skin cancer	2.08e-05	0.000718	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR—KRAS—skin cancer	2.08e-05	0.000718	CbGpPWpGaD
Lidocaine—EGFR—Direct p53 effectors—TP53—skin cancer	2.08e-05	0.000717	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB2—KRAS—skin cancer	2.07e-05	0.000714	CbGpPWpGaD
Lidocaine—EGFR—DAP12 signaling—KRAS—skin cancer	2.06e-05	0.000711	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—SHH—skin cancer	2.06e-05	0.00071	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—skin cancer	2.03e-05	0.0007	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—ENO2—skin cancer	2.03e-05	0.000698	CbGpPWpGaD
Lidocaine—EGFR—MAPK Signaling Pathway—KRAS—skin cancer	2.02e-05	0.000697	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—KRAS—skin cancer	2e-05	0.00069	CbGpPWpGaD
Lidocaine—EGFR—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	2e-05	0.000688	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—CSPG4—skin cancer	1.98e-05	0.000683	CbGpPWpGaD
Lidocaine—EGFR—Signaling by SCF-KIT—HRAS—skin cancer	1.98e-05	0.000682	CbGpPWpGaD
Lidocaine—EGFR—Integrated Breast Cancer Pathway—TP53—skin cancer	1.96e-05	0.000675	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—SMO—skin cancer	1.95e-05	0.000673	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—PTCH1—skin cancer	1.95e-05	0.000673	CbGpPWpGaD
Lidocaine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	1.95e-05	0.000673	CbGpPWpGaD
Lidocaine—EGFR—Fc epsilon receptor (FCERI) signaling—KRAS—skin cancer	1.94e-05	0.000669	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR in disease—KRAS—skin cancer	1.94e-05	0.000669	CbGpPWpGaD
Lidocaine—EGFR—DAP12 interactions—KRAS—skin cancer	1.94e-05	0.000669	CbGpPWpGaD
Lidocaine—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	1.93e-05	0.000665	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	1.92e-05	0.000663	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—KRAS—skin cancer	1.92e-05	0.000663	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—KRAS—skin cancer	1.92e-05	0.000663	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR—KRAS—skin cancer	1.92e-05	0.000663	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR in Cancer—KRAS—skin cancer	1.91e-05	0.000657	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—PTGER4—skin cancer	1.9e-05	0.000655	CbGpPWpGaD
Lidocaine—EGFR—Signaling by PDGF—KRAS—skin cancer	1.9e-05	0.000654	CbGpPWpGaD
Lidocaine—EGFR—Signaling by SCF-KIT—IL6—skin cancer	1.89e-05	0.000652	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling of activated FGFR—HRAS—skin cancer	1.89e-05	0.000652	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB4—HRAS—skin cancer	1.86e-05	0.000642	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—KRAS—skin cancer	1.85e-05	0.000639	CbGpPWpGaD
Lidocaine—SCN5A—Axon guidance—KRAS—skin cancer	1.83e-05	0.00063	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1.83e-05	0.000629	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PLIN2—skin cancer	1.82e-05	0.000626	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—CSPG4—skin cancer	1.82e-05	0.000626	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling of activated FGFR—IL6—skin cancer	1.81e-05	0.000624	CbGpPWpGaD
Lidocaine—EGFR—MAPK Signaling Pathway—TP53—skin cancer	1.8e-05	0.00062	CbGpPWpGaD
Lidocaine—EGFR—B Cell Activation—KRAS—skin cancer	1.8e-05	0.000619	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—GLI2—skin cancer	1.79e-05	0.000617	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—CDK4—skin cancer	1.78e-05	0.000615	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB4—IL6—skin cancer	1.78e-05	0.000614	CbGpPWpGaD
Lidocaine—EGFR—Downstream signal transduction—HRAS—skin cancer	1.78e-05	0.000613	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—HRAS—skin cancer	1.78e-05	0.000613	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PLIN2—skin cancer	1.78e-05	0.000612	CbGpPWpGaD
Lidocaine—EGFR—EGF/EGFR Signaling Pathway—HRAS—skin cancer	1.77e-05	0.00061	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR—HRAS—skin cancer	1.77e-05	0.00061	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB2—HRAS—skin cancer	1.76e-05	0.000607	CbGpPWpGaD
Lidocaine—EGFR—DAP12 signaling—HRAS—skin cancer	1.75e-05	0.000604	CbGpPWpGaD
Lidocaine—EGFR—Disease—SHH—skin cancer	1.74e-05	0.000599	CbGpPWpGaD
Lidocaine—EGFR—Disease—ENO2—skin cancer	1.74e-05	0.000599	CbGpPWpGaD
Lidocaine—EGFR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—skin cancer	1.73e-05	0.000595	CbGpPWpGaD
Lidocaine—EGFR—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	1.72e-05	0.000592	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MC1R—skin cancer	1.71e-05	0.000589	CbGpPWpGaD
Lidocaine—EGFR—Downstream signal transduction—IL6—skin cancer	1.7e-05	0.000587	CbGpPWpGaD
Lidocaine—SCN9A—Developmental Biology—IL6—skin cancer	1.7e-05	0.000587	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—HRAS—skin cancer	1.7e-05	0.000586	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR—IL6—skin cancer	1.69e-05	0.000584	CbGpPWpGaD
Lidocaine—EGFR—Signaling by ERBB2—IL6—skin cancer	1.69e-05	0.000581	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—GLI1—skin cancer	1.68e-05	0.00058	CbGpPWpGaD
Lidocaine—EGFR—DAP12 signaling—IL6—skin cancer	1.68e-05	0.000578	CbGpPWpGaD
Lidocaine—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	1.66e-05	0.000572	CbGpPWpGaD
Lidocaine—EGFR—DAP12 interactions—HRAS—skin cancer	1.65e-05	0.000568	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR in disease—HRAS—skin cancer	1.65e-05	0.000568	CbGpPWpGaD
Lidocaine—EGFR—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	1.65e-05	0.000568	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—HRAS—skin cancer	1.63e-05	0.000563	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—HRAS—skin cancer	1.63e-05	0.000563	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR—HRAS—skin cancer	1.63e-05	0.000563	CbGpPWpGaD
Lidocaine—SCN3A—Developmental Biology—IL6—skin cancer	1.63e-05	0.000561	CbGpPWpGaD
Lidocaine—EGFR—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.62e-05	0.000559	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR in Cancer—HRAS—skin cancer	1.62e-05	0.000558	CbGpPWpGaD
Lidocaine—EGFR—Signaling by PDGF—HRAS—skin cancer	1.61e-05	0.000556	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—SUFU—skin cancer	1.6e-05	0.00055	CbGpPWpGaD
Lidocaine—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	1.58e-05	0.000544	CbGpPWpGaD
Lidocaine—EGFR—DAP12 interactions—IL6—skin cancer	1.58e-05	0.000544	CbGpPWpGaD
Lidocaine—EGFR—Signaling by FGFR in disease—IL6—skin cancer	1.58e-05	0.000544	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—HRAS—skin cancer	1.58e-05	0.000543	CbGpPWpGaD
Lidocaine—SCN2A—Developmental Biology—IL6—skin cancer	1.56e-05	0.000539	CbGpPWpGaD
Lidocaine—SCN4A—Developmental Biology—IL6—skin cancer	1.56e-05	0.000539	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR—IL6—skin cancer	1.56e-05	0.000539	CbGpPWpGaD
Lidocaine—EGFR—Focal Adhesion—HRAS—skin cancer	1.56e-05	0.000537	CbGpPWpGaD
Lidocaine—SCN5A—Axon guidance—HRAS—skin cancer	1.55e-05	0.000535	CbGpPWpGaD
Lidocaine—EGFR—Signaling by EGFR in Cancer—IL6—skin cancer	1.55e-05	0.000534	CbGpPWpGaD
Lidocaine—EGFR—Signaling by PDGF—IL6—skin cancer	1.54e-05	0.000532	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PLIN2—skin cancer	1.54e-05	0.00053	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—NRAS—skin cancer	1.54e-05	0.000529	CbGpPWpGaD
Lidocaine—EGFR—Immune System—FOXO4—skin cancer	1.53e-05	0.000529	CbGpPWpGaD
Lidocaine—EGFR—B Cell Activation—HRAS—skin cancer	1.53e-05	0.000526	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—NRAS—skin cancer	1.51e-05	0.000522	CbGpPWpGaD
Lidocaine—SCN10A—Developmental Biology—IL6—skin cancer	1.51e-05	0.00052	CbGpPWpGaD
Lidocaine—SCN5A—Axon guidance—IL6—skin cancer	1.49e-05	0.000512	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—CSPG4—skin cancer	1.47e-05	0.000505	CbGpPWpGaD
Lidocaine—EGFR—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	1.46e-05	0.000503	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—CSPG4—skin cancer	1.43e-05	0.000494	CbGpPWpGaD
Lidocaine—EGFR—Disease—FOXO4—skin cancer	1.42e-05	0.000488	CbGpPWpGaD
Lidocaine—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.41e-05	0.000486	CbGpPWpGaD
Lidocaine—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	1.4e-05	0.000482	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—NRAS—skin cancer	1.39e-05	0.000479	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	1.38e-05	0.000474	CbGpPWpGaD
Lidocaine—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.35e-05	0.000466	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—ENO2—skin cancer	1.35e-05	0.000464	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PLIN2—skin cancer	1.34e-05	0.000462	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—KRAS—skin cancer	1.32e-05	0.000455	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—KRAS—skin cancer	1.3e-05	0.000449	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PLIN2—skin cancer	1.26e-05	0.000435	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PLIN2—skin cancer	1.25e-05	0.000432	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CSPG4—skin cancer	1.24e-05	0.000428	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—ENO2—skin cancer	1.23e-05	0.000425	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—SHH—skin cancer	1.22e-05	0.000419	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—RASA1—skin cancer	1.21e-05	0.000417	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—KRAS—skin cancer	1.2e-05	0.000412	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—ERCC2—skin cancer	1.18e-05	0.000406	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PTCH1—skin cancer	1.15e-05	0.000398	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—SMO—skin cancer	1.15e-05	0.000398	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—HRAS—skin cancer	1.12e-05	0.000387	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PTGER4—skin cancer	1.12e-05	0.000387	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—HRAS—skin cancer	1.11e-05	0.000382	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CSPG4—skin cancer	1.08e-05	0.000372	CbGpPWpGaD
Lidocaine—EGFR—Signaling by NGF—IL6—skin cancer	1.08e-05	0.000371	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PLIN2—skin cancer	1.07e-05	0.000369	CbGpPWpGaD
Lidocaine—SCN5A—Developmental Biology—IL6—skin cancer	1.06e-05	0.000365	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CSPG4—skin cancer	1.02e-05	0.000351	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—HRAS—skin cancer	1.02e-05	0.00035	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CSPG4—skin cancer	1.01e-05	0.000348	CbGpPWpGaD
Lidocaine—EGFR—Disease—ERCC2—skin cancer	1.01e-05	0.000348	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—ENO2—skin cancer	9.96e-06	0.000343	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—FOXO4—skin cancer	9.92e-06	0.000342	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—NRAS—skin cancer	9.92e-06	0.000342	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—ENO2—skin cancer	9.73e-06	0.000336	CbGpPWpGaD
Lidocaine—EGFR—Axon guidance—IL6—skin cancer	9.73e-06	0.000335	CbGpPWpGaD
Lidocaine—EGFR—Disease—TERT—skin cancer	9.46e-06	0.000326	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	9.21e-06	0.000318	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—NRAS—skin cancer	8.76e-06	0.000302	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CSPG4—skin cancer	8.63e-06	0.000297	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—KRAS—skin cancer	8.53e-06	0.000294	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—ENO2—skin cancer	8.43e-06	0.000291	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—NRAS—skin cancer	8.41e-06	0.00029	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PLIN2—skin cancer	8.26e-06	0.000285	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	8.19e-06	0.000282	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—ERCC2—skin cancer	7.82e-06	0.00027	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—KRAS—skin cancer	7.54e-06	0.00026	CbGpPWpGaD
Lidocaine—EGFR—Disease—BRAF—skin cancer	7.49e-06	0.000258	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—ENO2—skin cancer	7.35e-06	0.000253	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—HRAS—skin cancer	7.25e-06	0.00025	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—KRAS—skin cancer	7.24e-06	0.000249	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—ERCC2—skin cancer	7.17e-06	0.000247	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PTGS2—skin cancer	7.06e-06	0.000243	CbGpPWpGaD
Lidocaine—EGFR—Developmental Biology—IL6—skin cancer	6.94e-06	0.000239	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—ENO2—skin cancer	6.92e-06	0.000239	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—ENO2—skin cancer	6.86e-06	0.000237	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CSPG4—skin cancer	6.66e-06	0.000229	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TERT—skin cancer	6.63e-06	0.000228	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	6.59e-06	0.000227	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—HRAS—skin cancer	6.41e-06	0.000221	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—HRAS—skin cancer	6.15e-06	0.000212	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—IL6—skin cancer	6.13e-06	0.000211	CbGpPWpGaD
Lidocaine—EGFR—Disease—PTGS2—skin cancer	6.05e-06	0.000209	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—ENO2—skin cancer	5.86e-06	0.000202	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—ERCC2—skin cancer	5.78e-06	0.000199	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—ERCC2—skin cancer	5.65e-06	0.000195	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—NRAS—skin cancer	5.58e-06	0.000192	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	5.37e-06	0.000185	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—BRAF—skin cancer	5.25e-06	0.000181	CbGpPWpGaD
Lidocaine—EGFR—Immune System—NRAS—skin cancer	5.1e-06	0.000176	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—ERCC2—skin cancer	4.9e-06	0.000169	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—KRAS—skin cancer	4.8e-06	0.000166	CbGpPWpGaD
Lidocaine—EGFR—Disease—NRAS—skin cancer	4.71e-06	0.000162	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PTGS2—skin cancer	4.69e-06	0.000162	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	4.59e-06	0.000158	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ENO2—skin cancer	4.53e-06	0.000156	CbGpPWpGaD
Lidocaine—EGFR—Immune System—KRAS—skin cancer	4.39e-06	0.000151	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PTGS2—skin cancer	4.3e-06	0.000148	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—ERCC2—skin cancer	4.27e-06	0.000147	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—HRAS—skin cancer	4.08e-06	0.000141	CbGpPWpGaD
Lidocaine—EGFR—Disease—KRAS—skin cancer	4.05e-06	0.00014	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—ERCC2—skin cancer	4.02e-06	0.000139	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—ERCC2—skin cancer	3.99e-06	0.000137	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—IL6—skin cancer	3.91e-06	0.000135	CbGpPWpGaD
Lidocaine—EGFR—Immune System—HRAS—skin cancer	3.73e-06	0.000129	CbGpPWpGaD
Lidocaine—EGFR—Immune System—IL6—skin cancer	3.57e-06	0.000123	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PTGS2—skin cancer	3.47e-06	0.00012	CbGpPWpGaD
Lidocaine—EGFR—Disease—HRAS—skin cancer	3.45e-06	0.000119	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—ERCC2—skin cancer	3.41e-06	0.000117	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PTGS2—skin cancer	3.39e-06	0.000117	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—NRAS—skin cancer	3.3e-06	0.000114	CbGpPWpGaD
Lidocaine—EGFR—Disease—IL6—skin cancer	3.3e-06	0.000114	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PTGS2—skin cancer	2.94e-06	0.000101	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—KRAS—skin cancer	2.84e-06	9.78e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ERCC2—skin cancer	2.63e-06	9.06e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PTGS2—skin cancer	2.56e-06	8.82e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TP53—skin cancer	2.52e-06	8.69e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—HRAS—skin cancer	2.41e-06	8.31e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PTGS2—skin cancer	2.41e-06	8.31e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PTGS2—skin cancer	2.39e-06	8.24e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—IL6—skin cancer	2.31e-06	7.96e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PTGS2—skin cancer	2.04e-06	7.04e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PTGS2—skin cancer	1.58e-06	5.43e-05	CbGpPWpGaD
